Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer

Cancer Gene Therapy

Volumn 13, Issue 12, 2006, Pages 1082-1092

  Tsai, C H ^a   Hong, J H ^b   Hsieh, K F ^a   Hsiao, H W ^a   Chuang, W L ^a   Lee, C C ^b   McBride, W H ^c   Chiang, C S ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; IL 3; Mice; Radiation

Indexed keywords

DOXYCYCLINE; GAMMA INTERFERON; INTERLEUKIN 3; TETRACYCLINE;

ADENOVIRUS VECTOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL DEATH; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; IMMUNOGENICITY; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR RECURRENCE; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-3; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; TETRACYCLINE;

MURINAE;

EID: 33751060652     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700977     Document Type: Article

References (37)

1. Hillman GG, Slos P, Wang Y, Wright JL, Layer A, De Meyer M et al. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Therapy 2004; 11: 61-72.
2. Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL et al. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther 2003; 14: 763-775.
3. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174: 7516-7523.
4. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002; 8: 1765-1780.
5. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64: 7985-7994.
6. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64: 4328-4337.
7. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170: 6338-6347.
8. Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol 2004; 173: 2462-2469.
9. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F et al. A sense of danger from radiation. Radiat Res 2004; 162: 1-19.
10. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11: 3353-3362.
11. Chiang CS, Syljuasen RG, Hong JH, Wallis A, Dougherty GJ, McBride WH. Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo. Cancer Res 1997; 57: 3899-3903.
12. McBride WH, Dougherty GD, Wallis AE, Economou JS, Chiang CS. Interleukin-3 in gene therapy of cancer. Folia Biol 1994; 40: 62-73.
13. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res 1993; 53: 2112-2117.
14. Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penny DP, Lord EM et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex re-presentation of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci USA 1996; 93: 3669-3674.
15. Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol 1998; 160: 5773-5780.
16. Oh YT, Chen DW, Dougherty GJ, McBride WH. Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model. Int J Radiat Oncol Biol Phys 2004; 59: 579-583.
17. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-3443.
18. Gossen M, Bujard H. Efficacy of tetracycline-controlled gene expression is influenced by cell type: commentary. Biotechniques 1995; 19: 213-216; discussion 216-217.
19. Kimoto M, Kindler V, Higaki M, Ody C, Izui S, Vassalli P. Recombinant murine IL-3 fails to stimulate T or B lymphopoiesis in vivo, but enhances immune responses to T cell-dependent antigens. J Immunol 1988; 140: 1889-1894.
20. Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma. J Exp Ther Oncol 2003; 3: 161-168.
21. Dezso B, Haas GP, Hamzavi F, Kim S, Montecillo EJ, Benson PD et al. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases. Clin Cancer Res 1996; 2: 1543-1552.
22. Wong PM, Chung SW, Dunbar CE, Bodine DM, Ruscetti S, Nienhuis AW. Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder. Mol Cell Biol 1989; 9: 798-808.
23. Wu YZ, Hong JH, Huang HH, Dougherty GJ, McBride WH, Chiang CS. Mechanisms mediating the effects of IL-3 gene expression on tumor growth. J Leukoc Biol 2000; 68: 890-896.
24. Chiang CS, Hong JH, Wu YC, McBride WH, Dougherty GJ. Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Therapy 2000; 7: 1172-1178.
25. Frendl G, Beller DI. Regulation of macrophage activation by IL-3. I. IL-3 functions as a macrophage-activating factor with unique properties, inducing Ia and lymphocyte function-associated antigen-1 but not cytotoxicity. J Immunol 1990; 144: 3392-3399.
26. Chiang CS, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 1996; 97: 1512-1524.
27. Caux C, Vanbervliet B, Massacrier C, Durand I, Banchereau J. Interleukin-3 cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans cells from cord blood CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2376-2385.
28. Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG. IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother 1998; 21: 205-210.
29. Renneson J, Salio M, Mazouz N, Goldman M, Marchant A, Cerundolo V. Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8T cells. Clin Exp Immunol 2005; 139: 468-475.
30. Trakatelli M, Toungouz M, Blocklet D, Dodoo Y, Gordower L, Laporte M et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8(+) T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006; 55: 469-474.
31. Frendl G. Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol 1992; 14: 421-430.
32. Karulin AY, Hesse MD, Yip HC, Lehmann PV. Indirect IL-4 pathway in type 1 immunity. J Immunol 2002; 168: 545-553.
33. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224-2234.
34. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
35. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63: 7853-7860.
36. Dougherty GJ, McBride WH. Macrophage heterogeneity. J Clin Lab Immunol 1984; 14: 1-11.
37. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004; 24: 3335-3342.